Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cepheid Receives FDA Clearance For Xpert CT/NG, Delivering Rapid Detection And Differentiation Of Chlamydia And N. Gonorrhoeae
Cepheid announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert CT/NG. Running on Cepheid's GeneXpert Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). For the first time, same-day patient consultation and treatment is possible for the two most common sexually transmitted bacterial infections in the United States.
Latest Key Developments in Advanced
- Waters Corp Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 EPS Guidance-Conference Call
- Hologic Inc Updates FY 2013 Guidance To A Range In Line With Analysts' Estimates-Conference Call
- Arrhythmia Research Technology Inc Issues Q1 2013 Guidance; Announces Delay In Finalizing First Quarter Of 2013 Results
- Biosensors International Group Ltd Announces Incorporation Of New Subsidiaries
- Share this
- Link this
- Digg this
Follow Reuters